Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA

Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8

Uggh! What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE

Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F

Lower socioeconomic status (cluster 1) patients: ● older age at the diagnosis (37.9 vs. 32.6) ● longer diagnosis delay (7.8 vs. 6.8 years) ● higher BMI (27.6 vs. 25.9) ● greater structural damage vs cluster 2 Lopez-Medina C Abs0376 https://t.co/wXOksFGDKl #ACR22 @RheumNow https://t.co/1YVRA6r1sw

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Novel Aspects Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles Microvasc - Suspected/Established @RheumNow https://t.co/M8NWRSyH4p

#abs1235 #acr22 @rheumnow articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh

PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf

Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also ➣ more comorbidities ➣ higher prevalence of smoking ➣ worse disease activity ➣ higher use of anti-rheumatic drugs Ogdie A Abs0402 https://t.co/3E4qAuqgpI #ACR22 @RheumNow https://t.co/AaKxiQXMwx

Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb

What are we treating PMR with? RISE registry, 2016-20 (n=26,102 in US) - Such a small proportion ever see non-steroid therapies - Big chunk remain on steroids or lost to follow-up Surely we can improve PMR care! ABST1546 @SattuiSEMD @RADoctor #ACR22 @RheumNow https://t.co/Ocuw5WxKu2